Back to the homepage

About the study

About the study

A1chieve is a 60 000-person, global, prospective, observational study of basal, meal-time, and biphasic insulin analogs in daily clinical practice run by Novo Nordisk.

A1chieve[1,2] is a 60,000-person, global, prospective, observational study of basal, meal-time, and biphasic insulin analogs in daily clinical practice run by Novo Nordisk. The study evaluated adverse events and effectiveness of premix (biphasic insulin aspart 30 [NovoMix 30]), basal (insulin detemir [Levemir]), and meal-time (insulin aspart [NovoRapid]) insulin analogs in people with type 2 diabetes in near-routine clinical practice. A1chieve is an international, prospective, multi-centre, open-label, non-interventional, 24-week study of people with type 2 diabetes using an insulin analog. The study recruited 60 000 people[1] from 28 countries across four continents (Asia, Africa, South America, and Europe). The primary aim of the study is to assess the adverse event profile of the study insulins in routine clinical practice, including rates of hypoglycemia. In addition, effectiveness (HbA(1c), fasting plasma glucose, and postprandial plasma glucose) and patient quality of life outcomes were measured. Comprehensive epidemiological data were collected at baseline, including recent plasma glucose results and hypoglycemic episodes, prevalence of diabetes-related complications, and measures of current standards of care. Thus, A1chieve provides important information about how insulin analogs perform in daily clinical practice.[2]



1. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study. Diabetes Research and Clinical Practice 94 (2011) 353-363.

2. Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: Results from the A1chieve observational study. Diabetes Research and Clinical Practice 94 (2011) 364-370.

Search this site

Insulin Management Programme

The Progress in Insulin Management Resource Centre is a global, online educational platform created to help healthcare professionals and diabetes specialists to optimize their management of patients with type 1 and type 2 diabetes. Its key features include a free, online educational program on insulin management (10 courses in 3 content areas), selected and commented articles, summaries, infographics, webcasts, interviews, and e-learning modules.

You can register for free, start as many courses as you want simultaneously and get a certificate after course completion.

A1chieve Resource Centre Expert Panel

  • Philip Home

    Professor Philip Home

    Philip Home is Professor of Diabetes Medicine at Newcastle University and consultant physician in Newcastle, UK. Professor Home is Chairman of A1chieve® Global Advisory Board.

    Read more »

A1chieve results from bangladesh and ASEAN countries

Now available in the Resource Centre, the just published supplement to Diabetes Research and Clin...

Read more »